Fox Chase Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2023

  1. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers

    European Journal of Cancer Prevention, Vol. 32, Núm. 2, pp. 126-138

2020

  1. Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia

    Mathematical Biosciences and Engineering, Vol. 17, Núm. 5, pp. 4773-4800

  2. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2019

  1. The effects of time valuation in cancer optimal therapies: A study of chronic myeloid leukemia

    Theoretical Biology and Medical Modelling, Vol. 16, Núm. 1

2017

  1. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

    Nature Genetics, Vol. 49, Núm. 5, pp. 680-691

2014

  1. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

    Breast Cancer Research, Vol. 16

  2. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

    PLoS Genetics, Vol. 10, Núm. 4

  3. In situ methods for identifying the stem cell of the normal and cancerous breast

    Techniques and Methodological Approaches in Breast Cancer Research (Springer New York), pp. 151-182

2013

  1. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

    PLoS Genetics, Vol. 9, Núm. 3

2012

  1. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

    Cancer Epidemiology Biomarkers and Prevention, Vol. 21, Núm. 4, pp. 645-657

  2. Descriptive Biostatistics

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 17-32

  3. Equations: Formulating Biomedical Laws and Biomedical Magnitudes

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 129-199

  4. Game Theory

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 341-386

  5. Historical Introduction

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 1-24

  6. Inferential Biostatistics (I): Estimating Values of Biomedical Magnitudes

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 33-57

  7. Inferential Biostatistics (II): Estimating Biomedical Behaviors

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 59-127

  8. Optimal Control Theory: From Knowledge to Control (I). Basic Concepts

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 277-307

  9. Optimal Control Theory: From Knowledge to Control (II). Biomedical Applications

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 309-339

  10. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Human Mutation, Vol. 33, Núm. 4, pp. 690-702

  11. Systems of Equations: The Explanation of Biomedical Phenomena (I). Basic Questions

    EVOLUTION OF THE USE OF MATHEMATICS IN CANCER RESEARCH (SPRINGER), pp. 201-240